The Institute for Clinical and Economic Effectiveness’ draft cost-effectiveness report on the PCSK9 inhibitors has been updated in response to stakeholder comments and now suggests somewhat less of a price discount than originally thought necessary to allow the drugs to be considered cost-effective.
In its original draft report, released Sept. 8, ICER suggested discounts of at least 67% would be needed for Amgen Inc.’s Repatha and Sanofi and Regeneron Pharmaceuticals Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?